Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (86)

2024

  1. Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics

    International Journal of Pharmaceutics, Vol. 662

  2. Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning

    RMD Open, Vol. 10, Núm. 1

  3. Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis

    Nefrologia

2023

  1. Immunoglobulins in systemic sclerosis management. A large multicenter experience

    Autoimmunity Reviews, Vol. 22, Núm. 11

  2. SER recommendations for the treatment of uveitis

    Reumatologia Clinica, Vol. 19, Núm. 9, pp. 465-477

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting

    Reumatologia Clinica, Vol. 18, Núm. 10, pp. 567-573

  3. Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review

    Seminars in Arthritis and Rheumatism, Vol. 52

  4. Interobserver reliability of Masei index validation by a multicenter collaborative group of rheumatologists

    Rheumatology International, Vol. 42, Núm. 3, pp. 441-448

  5. Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology

    Reumatologia Clinica, Vol. 18, Núm. 5, pp. 253-259

  6. Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment

    Expert Opinion on Biological Therapy, Vol. 22, Núm. 7, pp. 821-829

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

  2. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  3. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

    BMC Musculoskeletal Disorders, Vol. 22, Núm. 1

  4. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

  5. Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 160-169

2020

  1. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children

    Pediatric Rheumatology, Vol. 18, Núm. 1

  2. Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross-Sectional Study

    Arthritis Care and Research, Vol. 72, Núm. 6, pp. 822-828

  3. Influence of MUC5B gene on antisynthetase syndrome

    Scientific Reports, Vol. 10, Núm. 1

  4. Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part I: Diagnosis, Evaluation and Treatment

    Reumatologia Clinica, Vol. 16, Núm. 2P1, pp. 71-86